SG11201408152VA - Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency - Google Patents
Hgh-xten fusion protein and its use in the treatment of growth hormone deficiencyInfo
- Publication number
- SG11201408152VA SG11201408152VA SG11201408152VA SG11201408152VA SG11201408152VA SG 11201408152V A SG11201408152V A SG 11201408152VA SG 11201408152V A SG11201408152V A SG 11201408152VA SG 11201408152V A SG11201408152V A SG 11201408152VA SG 11201408152V A SG11201408152V A SG 11201408152VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- hgh
- fusion protein
- growth hormone
- xten
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 206010056438 Growth hormone deficiency Diseases 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 101000642591 Xenopus laevis Somatotropin-A Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011285 therapeutic regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 December 2013 (12.12.2013) WIPOIPCT (10) International Publication Number WO 2013/184216 A1 (51) International Patent Classification: A61K 38/27 (2006.01) A61P 5/00 (2006.01) A61K 47/42 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 61/689, 390 61/663,475 61/763, 753 PCT/US2013/031673 14 March 2013 (14.03.2013) English English US US us 5 June 2012 (05.06.2012) 22 June 2012 (22.06.2012) 12 February 2013 (12.02.2013) (71) Applicant (for all designated States except US): AMUNIX OPERATING INC. [US/US]; 500 Ellis Street, Mountain View, CA 94043-2206 (US). (72) Inventors; and (71) Applicants (for US only): CLELAND, Jeffrey L. [US/US]; 225 Aberdeen Drive, San Carlos, CA 94070 (US). BRIGHT, George M. [US/US]; 9 Rockwood Court, San Mateo, CA 94403 (US). HUMPHRISS, Eric [US/US]; 550 Morey Drive, Menlo Park, CA 94025 (US). SCHELLENBERGER, Volker [DE/US]; 914 Moreno Avenue, Palo Alto, CA 94303 (US). SILVERMAN, Joshua [US/US]; 829 Dartshire Way, Sunnyvale, CA 94087 (US). STEMMER, Willem P. [NL/US]; 108 Kathy Court, Los Gatos, CA 95051 (US). WANG, Chia-Wei [—/US]; 1449 David Lane, Milpitas, CA 95035 (US). GEETHING, Nathan [US/US]; 213 Cll Zorzal, San Juan, Puerto Rico 00926 (US). SPINK, Benjamin [GB/US]; 379 Northam Avenue, San Carlos, CA 94070 (US). (74) Agents: ORBAI, Lucian et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) V© i-H CJ •t 00 i-H o CJ (54) Title: HGH-XTEN FUSION PROTEIN AND ITS USE IN THE TREATMENT OF GROWTH HORMONE DEFICIENCY (57) Abstract: The present invention concerns an improved therapeutic regimen for GHD therapy. In particular, the invention con cerns methods for bolus dose administration of human growth hormone- a XTEN (hGH-XTEN) fusion protein.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261689390P | 2012-06-05 | 2012-06-05 | |
| US201261663475P | 2012-06-22 | 2012-06-22 | |
| US201361763753P | 2013-02-12 | 2013-02-12 | |
| PCT/US2013/031673 WO2013184216A1 (en) | 2012-06-05 | 2013-03-14 | Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408152VA true SG11201408152VA (en) | 2015-01-29 |
Family
ID=47998551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408152VA SG11201408152VA (en) | 2012-06-05 | 2013-03-14 | Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20140162949A1 (en) |
| EP (1) | EP2858664B1 (en) |
| JP (2) | JP2015520188A (en) |
| KR (1) | KR20150021072A (en) |
| CN (2) | CN107320719A (en) |
| AU (1) | AU2013272220A1 (en) |
| BR (1) | BR112014030404A2 (en) |
| CA (1) | CA2875827A1 (en) |
| DK (1) | DK2858664T3 (en) |
| ES (1) | ES2733220T3 (en) |
| HK (1) | HK1208629A1 (en) |
| IL (1) | IL236070A0 (en) |
| MX (1) | MX2014014927A (en) |
| NZ (1) | NZ702557A (en) |
| PH (1) | PH12014502738A1 (en) |
| SG (1) | SG11201408152VA (en) |
| WO (1) | WO2013184216A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| MX362028B (en) | 2009-02-03 | 2019-01-04 | Amunix Pharmaceuticals Inc | Extended recombinant polypeptides and compositions comprising same. |
| US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| JP2016514132A (en) * | 2013-03-11 | 2016-05-19 | アムニクス オペレーティング インコーポレイテッド | Treatment of childhood growth hormone deficiency with human growth hormone analogues |
| AU2016315656A1 (en) | 2015-08-28 | 2018-02-01 | Amunix Pharmaceuticals, Inc. | Chimeric polypeptide assembly and methods of making and using the same |
| WO2017136583A1 (en) | 2016-02-02 | 2017-08-10 | Versartis, Inc. | Growth hormone treatment adherence system |
| WO2017142331A1 (en) * | 2016-02-17 | 2017-08-24 | Genexine, Inc. | Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency |
| RU2732113C2 (en) * | 2016-02-17 | 2020-09-11 | Дженексин, Инк. | Pharmaceutical composition comprising recombinant human growth hormone for treating growth hormone deficiency |
| EP3491012A4 (en) * | 2016-07-27 | 2020-07-01 | Amunix Operating Inc. | Treatment of adult growth hormone deficiency with human growth hormone analogues |
| CN113597434B (en) | 2019-12-31 | 2022-07-01 | 北京质肽生物医药科技有限公司 | Fusion proteins of GLP-1 and GDF15 and conjugates thereof |
| CN113728013B (en) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Conjugates of fusion proteins of GLP-1 and FGF21 |
| CN115925995A (en) | 2020-09-30 | 2023-04-07 | 北京质肽生物医药科技有限公司 | Polypeptide Conjugates and Methods of Use |
| CN116554343B (en) * | 2022-01-30 | 2024-07-12 | 领诺(上海)医药科技有限公司 | Long-acting recombinant human growth hormone and application thereof |
| CN116003632A (en) * | 2022-12-07 | 2023-04-25 | 北京大学 | Long-acting slow-release human recombinant growth hormone fusion protein, and pharmaceutical composition and application thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898830A (en) | 1979-07-05 | 1990-02-06 | Genentech, Inc. | Human growth hormone DNA |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| JP2002512624A (en) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | Method for producing non-immunogenic protein |
| US6406632B1 (en) | 1998-04-03 | 2002-06-18 | Symyx Technologies, Inc. | Rapid characterization of polymers |
| GB9815157D0 (en) | 1998-07-13 | 1998-09-09 | Metron Designs Ltd | High resolution pulse width setting from relatively low frequency clocks |
| US20030228309A1 (en) | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| US7294513B2 (en) | 2002-07-24 | 2007-11-13 | Wyatt Technology Corporation | Method and apparatus for characterizing solutions of small particles |
| MX362028B (en) * | 2009-02-03 | 2019-01-04 | Amunix Pharmaceuticals Inc | Extended recombinant polypeptides and compositions comprising same. |
| US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| US8703717B2 (en) * | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| MX354555B (en) * | 2009-06-08 | 2018-03-09 | Amunix Operating Inc | Growth hormone polypeptides and methods of making and using same. |
-
2013
- 2013-03-14 AU AU2013272220A patent/AU2013272220A1/en not_active Abandoned
- 2013-03-14 CA CA2875827A patent/CA2875827A1/en not_active Abandoned
- 2013-03-14 CN CN201710596161.5A patent/CN107320719A/en not_active Withdrawn
- 2013-03-14 US US13/829,369 patent/US20140162949A1/en not_active Abandoned
- 2013-03-14 BR BR112014030404A patent/BR112014030404A2/en not_active IP Right Cessation
- 2013-03-14 JP JP2015516010A patent/JP2015520188A/en active Pending
- 2013-03-14 DK DK13712656.1T patent/DK2858664T3/en active
- 2013-03-14 CN CN201380041556.9A patent/CN104519903A/en active Pending
- 2013-03-14 ES ES13712656T patent/ES2733220T3/en active Active
- 2013-03-14 MX MX2014014927A patent/MX2014014927A/en unknown
- 2013-03-14 NZ NZ702557A patent/NZ702557A/en not_active IP Right Cessation
- 2013-03-14 EP EP13712656.1A patent/EP2858664B1/en active Active
- 2013-03-14 SG SG11201408152VA patent/SG11201408152VA/en unknown
- 2013-03-14 KR KR20147036167A patent/KR20150021072A/en not_active Application Discontinuation
- 2013-03-14 WO PCT/US2013/031673 patent/WO2013184216A1/en active Application Filing
-
2014
- 2014-12-04 IL IL236070A patent/IL236070A0/en unknown
- 2014-12-05 PH PH12014502738A patent/PH12014502738A1/en unknown
-
2015
- 2015-09-24 HK HK15109368.8A patent/HK1208629A1/en unknown
-
2017
- 2017-03-08 JP JP2017043512A patent/JP2017125051A/en active Pending
- 2017-07-13 US US15/648,967 patent/US20180051063A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013272220A1 (en) | 2015-01-15 |
| PH12014502738A1 (en) | 2015-02-02 |
| ES2733220T3 (en) | 2019-11-28 |
| JP2015520188A (en) | 2015-07-16 |
| MX2014014927A (en) | 2015-05-15 |
| CN104519903A (en) | 2015-04-15 |
| BR112014030404A2 (en) | 2017-06-27 |
| CA2875827A1 (en) | 2013-12-12 |
| US20180051063A1 (en) | 2018-02-22 |
| HK1208629A1 (en) | 2016-03-11 |
| NZ702557A (en) | 2017-06-30 |
| EP2858664B1 (en) | 2019-05-08 |
| WO2013184216A1 (en) | 2013-12-12 |
| DK2858664T3 (en) | 2019-07-08 |
| US20140162949A1 (en) | 2014-06-12 |
| KR20150021072A (en) | 2015-02-27 |
| CN107320719A (en) | 2017-11-07 |
| JP2017125051A (en) | 2017-07-20 |
| EP2858664A1 (en) | 2015-04-15 |
| IL236070A0 (en) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408152VA (en) | Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201910182RA (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201407819UA (en) | Improved methods of cell culture for adoptive cell therapy | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201407548UA (en) | Treatment of amd using aav sflt-1 | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201406625XA (en) | Anti-fcrn antibodies | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201407512VA (en) | High-concentration monoclonal antibody formulations | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201408347UA (en) | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides | |
| SG11201407205WA (en) | System and process for retina phototherapy | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408405WA (en) | Engineered three-dimensional connective tissue constructs and methods of making the same |